The U.S. Defense Health Agency awarded a $1,134,000 Project Grant to President and Fellows of Harvard College (Harvard University) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "NOVEL BRAIN SHUTTLE-MEDIATED ANTI-TDP-43 THERAPEUTICS FOR AMYOTROPHIC LATERAL SCLEROSIS," supports research to develop novel treatments for amyotrophic lateral sclerosis (ALS) by leveraging brain shuttle technologies. The project will be conducted at Harvard University's research facilities in Cambridge, MA and is expected to be completed by April 14, 2025. This federal grant award enables Harvard's researchers to pursue innovative biomedical research focused on addressing critical medical needs for military service members and the broader population.